TR201908514T4 - İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇ - Google Patents

İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇ Download PDF

Info

Publication number
TR201908514T4
TR201908514T4 TR2019/08514T TR201908514T TR201908514T4 TR 201908514 T4 TR201908514 T4 TR 201908514T4 TR 2019/08514 T TR2019/08514 T TR 2019/08514T TR 201908514 T TR201908514 T TR 201908514T TR 201908514 T4 TR201908514 T4 TR 201908514T4
Authority
TR
Turkey
Prior art keywords
morfinane
derivatives
drug overdose
treatment
overdose treatment
Prior art date
Application number
TR2019/08514T
Other languages
English (en)
Inventor
Silverman Bernard
Fu Fen-Ni
Guo Chengyun
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Publication of TR201908514T4 publication Critical patent/TR201908514T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Mevcut uygulama, ilaç toksisitesi ve aşırı doz tedavisinde sürdürülebilir etkinliğe sahip Formül I'i içeren morfinan türevleri ile ilgilidir.
TR2019/08514T 2009-12-04 2010-10-13 İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇ TR201908514T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26688109P 2009-12-04 2009-12-04

Publications (1)

Publication Number Publication Date
TR201908514T4 true TR201908514T4 (tr) 2019-07-22

Family

ID=44082631

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/08514T TR201908514T4 (tr) 2009-12-04 2010-10-13 İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇

Country Status (19)

Country Link
US (4) US9119848B2 (tr)
EP (2) EP3569234A1 (tr)
JP (2) JP5691042B2 (tr)
AU (1) AU2010326676B2 (tr)
CA (1) CA2782529C (tr)
CY (1) CY1121646T1 (tr)
DK (1) DK2506712T3 (tr)
ES (1) ES2729679T3 (tr)
HR (1) HRP20191029T1 (tr)
HU (1) HUE043963T2 (tr)
LT (1) LT2506712T (tr)
ME (1) ME03468B (tr)
NZ (1) NZ600379A (tr)
PL (1) PL2506712T3 (tr)
PT (1) PT2506712T (tr)
RS (1) RS58894B1 (tr)
SI (1) SI2506712T1 (tr)
TR (1) TR201908514T4 (tr)
WO (1) WO2011068594A1 (tr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012006069A8 (pt) * 2009-09-18 2017-10-10 Adolor Corp Método para tratar ou prevenir constipação induzida e disfunção intestinal induzida por opióide em um humano, e, uso de uma quantidade terapeuticamente efetiva de composto
HUE043963T2 (hu) 2009-12-04 2019-09-30 Alkermes Pharma Ireland Ltd Morfinán származékok gyógyszer-túladagolás kezelésére
PL2608670T3 (pl) 2010-08-23 2019-05-31 Alkermes Pharma Ireland Ltd Sposoby leczenia przyrostu masy ciała wywołanego neuroleptykiem
US8627816B2 (en) * 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
MX2014007042A (es) 2011-12-15 2015-01-22 Alkermes Pharma Ireland Ltd Composiciones de la buprenorfina y antagonistas de los receptores opioide-mu.
WO2013088242A1 (en) * 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Samidorphan (alks 33) in combination with opioid agonists
US10195191B2 (en) 2011-12-15 2019-02-05 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
JP2016519161A (ja) 2013-05-24 2016-06-30 アルカームス ファーマ アイルランド リミテッド モルファン及びモルフィナン類似物及び使用の方法
US9656961B2 (en) 2013-05-24 2017-05-23 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
US10550088B2 (en) 2013-12-27 2020-02-04 Purdue Pharma L.P. 6-substituted and 7-substituted morphinan analogs and the use thereof
WO2015192053A1 (en) * 2014-06-13 2015-12-17 Purdue Pharma L.P. Azamophinan derivatives and use thereof
US9517307B2 (en) 2014-07-18 2016-12-13 Kaleo, Inc. Devices and methods for delivering opioid antagonists including formulations for naloxone
US9763572B2 (en) * 2015-02-17 2017-09-19 Children's Hospital Medical Center Quantitative pupillometry as a bedside predictor of postoperative respiratory depression
WO2022101444A1 (en) 2020-11-12 2022-05-19 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB874217A (en) 1958-10-30 1961-08-02 Albert Boehringer Normorphine derivatives
US3332950A (en) 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
CH581624A5 (tr) 1970-08-14 1976-11-15 Sumitomo Chemical Co
US3856795A (en) * 1972-04-25 1974-12-24 American Home Prod Process for preparation of secondary amines from tertiary amines
DE2254298A1 (de) 1972-11-06 1974-05-16 Boehringer Sohn Ingelheim Neue (heteroarylmethyl)-normorphine, deren saeureadditionssalze, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
US3957793A (en) * 1974-09-20 1976-05-18 Sterling Drug Inc. Hydroxyiminobenzazocines
US4032529A (en) * 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US4127577A (en) * 1975-11-24 1978-11-28 Sterling Drug Inc. Aminomethanobenzazocine process
US4205171A (en) * 1976-01-12 1980-05-27 Sterling Drug Inc. Aminomethanobenzazocines and nitromethanobenzazocines
US4161597A (en) 1976-12-20 1979-07-17 Research Corporation N-alkyl-14-hydroxymorphinans and derivatives
US4100228A (en) 1977-04-04 1978-07-11 The Dow Chemical Company Transparent impact styrene polymer structure
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4373139A (en) 1979-04-30 1983-02-08 Motorola, Inc. Detectors
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
FR2514644A1 (fr) 1981-10-19 1983-04-22 Sanofi Sa Composition pharmaceutique a action antagoniste peripherique des opiaces
US4374139A (en) 1981-11-09 1983-02-15 Hoffmann-La Roche Inc. Levorotatory N-substituted acylmorphinans useful as analgesic agents
DE3220831A1 (de) 1982-06-03 1983-12-08 Boehringer Ingelheim KG, 6507 Ingelheim N-(2-methoxyethyl)-noroxymorphon, dessen saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu deren herstellung
US4451470A (en) 1982-07-06 1984-05-29 E. I. Du Pont De Nemours And Company Analgesic, antagonist, and/or anorectic 14-fluoromorphinans
US4649200A (en) * 1986-05-08 1987-03-10 Regents Of The University Of Minnesota Substituted pyrroles with opioid receptor activity
US4939264A (en) 1986-07-14 1990-07-03 Abbott Laboratories Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies
US4929622A (en) 1987-09-24 1990-05-29 Hoechst-Roussel Pharmaceuticals, Inc. 2,6-Methanopyrrolo-3-benzazocines
US5270328A (en) 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
US5250542A (en) 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
US5159081A (en) 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US5258386A (en) * 1991-06-05 1993-11-02 The United States Of America As Represented By The Secretary Of The Army (+)-3-substituted-N alkylmorphinans, synthesis and use as anticonvulsant and neuroprotective agents
US5607941A (en) * 1992-06-26 1997-03-04 Boehringer Ingelheim Kg Useful for treating neurodegenerative diseases
SE9103745D0 (sv) 1991-12-18 1991-12-18 Wikstroem Haakan Aryl-triflates and related compounds
EP0632041A1 (en) 1993-07-01 1995-01-04 Katholieke Universiteit Nijmegen New morphine derivatives having improved analgesic and narcotic properties
US5434171A (en) 1993-12-08 1995-07-18 Eli Lilly And Company Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates
TR199801348T2 (tr) 1996-01-10 1998-10-21 Smithkline Beecham S.P.A. Heterosikl-kondanse morfinoid türevleri(II).
GB9616253D0 (en) 1996-08-01 1996-09-11 Johnson Matthey Plc Preparation of narcotic analgesics
ES2121553B1 (es) 1996-12-23 1999-06-16 Univ Santiago Compostela Nuevos endoperoxidos morfinicos funcionalizados en posiciones c-6 y c-14 del anillo c y procedimiento para su obtencion.
GB9709972D0 (en) 1997-05-19 1997-07-09 Pfizer Ltd Tetrazoles
GB9912411D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
WO2001012197A1 (en) 1999-08-13 2001-02-22 Southern Research Institute Pyridomorphinans, thienomoprhinans and use thereof
EP1244447B1 (en) 1999-11-29 2007-01-10 Adolor Corporation Novel methods and compositions involving opioids and antagonists thereof
EP1944292B9 (en) 2000-10-31 2016-07-06 Rensselaer Polytechnic Institute 8-substituted-2,6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
US7375082B2 (en) 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
ES2305457T3 (es) 2002-03-20 2008-11-01 Euro-Celtique S.A. Metodo de administracion de buprenorfina para tratar la depresion.
DE60302157T2 (de) 2002-05-30 2006-07-27 Eli Lilly And Co., Indianapolis Opioidrezeptorantagonisten
WO2004005924A1 (en) 2002-07-03 2004-01-15 Spinelix 3d microarray
DE10229842A1 (de) 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
WO2004007449A1 (en) 2002-07-16 2004-01-22 Rensselaer Polytechnic Institute Process for conversion of phenols to carboxamides via the succinimide esters
AU2003298691A1 (en) 2002-11-18 2004-06-15 The Mclean Hospital Corporation Mixed kappa/mu opioids and uses thereof
US20040192715A1 (en) * 2003-02-05 2004-09-30 Mark Chasin Methods of administering opioid antagonists and compositions thereof
DK2316456T3 (en) 2003-04-29 2017-09-11 Orexigen Therapeutics Inc Compositions for affecting weight loss comprising an opioid antagonist and bupropion
KR20060134041A (ko) 2004-04-22 2006-12-27 모르 리서치 애플리케이션즈 리미티드 음식물 섭취 관리 방법
EP1748978B1 (en) * 2004-05-14 2014-06-04 Janssen Pharmaceutica NV Carboxamido opioid compounds
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
BRPI0517091B8 (pt) * 2004-11-05 2021-05-25 Rensselaer Polytech Inst composto 4-hidroxibenzomorfano substituído na posição-3 por carboxamida ou tiocarboxamida
US9662390B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2422579T3 (es) 2005-07-21 2013-09-12 Rensselaer Polytech Inst 2,6-Metano-3-benzazocinas 8-carboxamido sustituidas y 3-carboxamido morfanos sustituidos como ligandos de los receptores opioides
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
WO2007067714A2 (en) 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
US20090214650A1 (en) * 2006-02-01 2009-08-27 Alkermes, Inc. Methods of Treating alcoholism and alcohol related disorders using combination drug therapy and swellable polymers
CA2663909A1 (en) 2006-09-20 2008-03-27 Mallinckrodt Inc. Preparation of substituted morphinan-6-ones and salts and intermediates thereof
CA2670342A1 (en) 2006-11-22 2008-06-12 Progenics Pharmaceuticals, Inc. N-oxides of 4,5-epoxy-morphinanium analogs
US9040726B2 (en) 2007-03-06 2015-05-26 Mallinckrodt Llc Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
CN101677971A (zh) 2007-03-19 2010-03-24 阿卡蒂亚药品公司 5-ht2a反向激动剂和拮抗剂与抗精神病药物的组合
JP2010527374A (ja) 2007-05-16 2010-08-12 レンセラール ポリテクニック インスティチュート 縮合環複素環オピオイド
BRPI0815020A2 (pt) 2007-08-09 2015-03-10 Rensselaer Polytech Inst Composto, e, métodos de aliviar um efeito colateral de um opiato em um paciente que recebeu um opiato, e de melhorar função do intestino pós-operatório em um paciente que se submeteu a cirurgia.
US8354534B2 (en) * 2008-02-14 2013-01-15 Alkermes, Inc. Selective opioid compounds
US8138169B2 (en) 2008-04-11 2012-03-20 Comgenrx, Inc. Combination therapy for bipolar disorder
AU2009274147B2 (en) 2008-07-21 2014-09-04 Rensselaer Polytechnic Institute Large substituent, non-phenolic amine opioids
AU2009342654B2 (en) * 2009-03-19 2013-09-05 Alkermes Pharma Ireland Limited Morphinan derivatives with high oral bioavailability
US20120149724A1 (en) 2009-06-04 2012-06-14 The General Hospital Corporation Modulating endogenous beta-endorphin levels
HUE043963T2 (hu) 2009-12-04 2019-09-30 Alkermes Pharma Ireland Ltd Morfinán származékok gyógyszer-túladagolás kezelésére
ES2582306T3 (es) 2010-03-22 2016-09-12 Rensselaer Polytechnic Institute Derivados de morfinano que contienen un grupo carboxamida como ligandos de receptores opioides
CA2804940C (en) 2010-07-08 2017-03-07 Alkermes Pharma Ireland Limited Process for the synthesis of substituted morphinans
PL2601196T3 (pl) 2010-08-04 2014-09-30 Mallinckrodt Llc N-demetylowanie 6-ketomorfinanów
PL2608670T3 (pl) 2010-08-23 2019-05-31 Alkermes Pharma Ireland Ltd Sposoby leczenia przyrostu masy ciała wywołanego neuroleptykiem
EP2655332B1 (en) 2010-12-23 2016-07-13 Phoenix Pharmalabs, Inc. Novel morphinans useful as analgesics
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
MX2014007042A (es) 2011-12-15 2015-01-22 Alkermes Pharma Ireland Ltd Composiciones de la buprenorfina y antagonistas de los receptores opioide-mu.

Also Published As

Publication number Publication date
JP2015038139A (ja) 2015-02-26
CY1121646T1 (el) 2020-07-31
PL2506712T3 (pl) 2019-09-30
HUE043963T2 (hu) 2019-09-30
US20160051535A1 (en) 2016-02-25
AU2010326676B2 (en) 2013-03-14
JP2013512901A (ja) 2013-04-18
HRP20191029T1 (hr) 2019-09-20
EP2506712B8 (en) 2019-06-19
JP5691042B2 (ja) 2015-04-01
EP2506712A1 (en) 2012-10-10
JP6216305B2 (ja) 2017-10-18
CA2782529A1 (en) 2011-06-09
US20200345718A1 (en) 2020-11-05
WO2011068594A1 (en) 2011-06-09
ME03468B (me) 2020-01-20
RS58894B1 (sr) 2019-08-30
AU2010326676A2 (en) 2012-08-30
EP3569234A1 (en) 2019-11-20
US20170333422A1 (en) 2017-11-23
US20110136848A1 (en) 2011-06-09
LT2506712T (lt) 2019-06-25
DK2506712T3 (da) 2019-06-03
EP2506712B1 (en) 2019-03-27
SI2506712T1 (sl) 2019-06-28
ES2729679T3 (es) 2019-11-05
CA2782529C (en) 2015-05-26
PT2506712T (pt) 2019-05-31
US9119848B2 (en) 2015-09-01
NZ600379A (en) 2014-05-30
EP2506712A4 (en) 2013-07-10
AU2010326676A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
TR201908514T4 (tr) İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
MA33939B1 (fr) 5-alcynyl-pyrimidines
DE602008000754D1 (de) Tropanverbindungen
MX2009009428A (es) Analogos de ciclopamina heterociclicos y metodos de uso de los mismos.
IN2012DN01233A (tr)
TW200800987A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
HK1139930A1 (en) Cyclopamine lactam analogs and methods of use thereof
MX2015005963A (es) Inhibidores heterociclicos de glutaminasa.
UA102858C2 (ru) Производные пиридино-пиридинонов, способ их получения и применения в терапии
EA201070237A1 (ru) Четвертичные опиоидные карбоксамиды
TR201708567T4 (tr) Sigma ligandların kemik kanseri ağrısında kullanımı.
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
SG148192A1 (en) Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents
MX2015007053A (es) Compuestos dimericos.
MX2009004358A (es) Suministro transdermico de derivados polares de cetoprofeno.
TW200942530A (en) Pyridine compounds
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
MX342947B (es) Tratamiento de diabetes tipo 2.
MY183039A (en) Pyridin-2-yl derivatives as immunomodulating agents
MX2009010483A (es) 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.
MX2011011767A (es) Combinacion antitumoral que comprende ave8062 y sorafenib.
TW200716577A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases